Onychomycosis Market Report 2026

The onychomycosis market size has grown strongly in recent years. It will grow from $3.81 billion in 2025 to $4.03 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to high prevalence of onychomycosis, limited availability of advanced antifungal drugs, increasing fungal nail infections due to aging population, growing awareness among dermatologists, early adoption of topical treatments.

The onychomycosis market size is expected to see strong growth in the next few years. It will grow to $5.09 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to rising demand for combination therapies, increasing adoption of teledermatology and remote monitoring, growing development of ai-assisted diagnostic solutions, expansion of hospital and retail pharmacy distribution, increasing investment in research for resistant fungal strains. Major trends in the forecast period include rising adoption of personalized antifungal therapies, increasing use of teledermatology for diagnosis and monitoring, growing implementation of ai-based diagnostic tools for nail infections, rising awareness about nail health and hygiene, increasing development of combination drug and topical therapies.

The increasing diabetic population is expected to drive the growth of the onychomycosis market in the coming years. Diabetes is a chronic condition caused by insufficient insulin production or the body’s ineffective use of insulin. Onychomycosis, a common nail infection, is more prevalent among people with diabetes and requires proper management to prevent complications. For instance, in June 2024, the National Health Service (NHS), a UK-based government organization, reported that over 549,000 additional individuals in England were at risk of developing type 2 diabetes in 2023, bringing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This marked an increase of nearly 20% from 3,065,825 in 2022. Therefore, the rising prevalence of diabetes is fueling demand for onychomycosis treatments.

Leading companies in the onychomycosis market are focusing on innovative formulations to enhance treatment outcomes and strengthen their market positions. Innovative formulations help target the condition more effectively while minimizing systemic exposure. For example, in February 2024, Moberg Pharma AB, a Sweden-based pharmaceutical company, launched MOB-015, a proprietary topical terbinafine formulation designed to deliver therapeutic concentrations directly to the nail and nail bed. MOB-015 has received national approval recommendations in 13 European countries and is marketed in Sweden under the brand Terclara. Supported by two Phase 3 trials, the formulation achieved superior mycological cure rates (76% vs. up to 42% for comparators) and a significantly higher complete cure rate, with no serious adverse events reported.

In July 2023, Cipher Pharmaceuticals Inc., a Canada-based pharmaceutical company, partnered with Moberg Pharma to commercialize MOB-015 for nail fungus treatment. The collaboration aims to launch the product across 13 European countries following EU approval, bringing an effective topical onychomycosis solution to a wider patient population. Moberg Pharma AB is a Sweden-based company specializing in onychomycosis treatments.

Major companies operating in the onychomycosis market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sandoz International GmbH, Bausch Health Companies Inc., Perrigo Company plc, Galderma Laboratories LP, Aurobindo Pharma Limited, Cipla Inc., Dr.Reddy's Laboratories Ltd., Apotex Inc, Lupin Limited, Amneal Pharmaceuticals Inc., Alembic Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Mayne Pharma Group Limited, Wockhardt Ltd., Jubilant Cadista Pharmaceuticals Inc., Moberg Pharma AB, Medimetriks Pharmaceuticals Inc., Blueberry Therapeutics Ltd., Hallux Inc., NovaBiotics Ltd., Zydus Cadila Healthcare Limited.

North America was the largest region in the onychomycosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onychomycosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the onychomycosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the onychomycosis market by increasing costs of imported antifungal drugs, topical formulations, and advanced diagnostic tools. Regions like north america, europe, and asia-pacific are most affected due to reliance on imported dermatology products and devices. While tariffs may elevate treatment costs, they also drive local production, encourage innovation in cost-effective therapies, and promote development of domestic diagnostic and treatment solutions.

The onychomycosis market research report is one of a series of new reports that provides onychomycosis market statistics, including onychomycosis industry global market size, regional shares, competitors with a onychomycosis market share, detailed onychomycosis market segments, market trends and opportunities, and any further data you may need to thrive in the onychomycosis industry. This onychomycosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Onychomycosis is a fungal infection that affects the nail matrix, bed, or plate, impacting both toenails and fingernails. It can cause nail discoloration, thickening, and crumbling. The aim of treatment is to eliminate the infection, restore the nail’s health and appearance, and prevent the fungus from spreading to other nails or skin.

The main types of onychomycosis include distal subungual onychomycosis (DSO), white superficial onychomycosis (WSO), proximal subungual onychomycosis (PSO), candida onychomycosis, and others. Distal subungual onychomycosis (DSO) is a fungal infection of the toenails, which can be treated using oral antifungal drugs, topical antifungal treatments, or a combination of both. Treatment options include drug therapy, topical therapy, and others, and these are distributed through hospital pharmacies, retail pharmacies, and other channels.

The onychomycosis market includes revenues earned by services such as combination therapy, oral antifungal medications, itraconazole, ketoconazole, griseofulvin, and terbinafine. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.